In summer 2018, drug regulatory authorities first became aware of nitrosamine impurities in various medicinal products. Since then, Swissmedic has evaluated and overseen measures to avoid impurities of this kind. Tests have been developed internationally to assess potential risks and have been applied to determine acceptable intakes. These requirements also form the basis in Switzerland for avoiding impurities of this kind in medicinal products to the largest extent possible and for ensuring that patients are supplied with safe medicines.
www.swissmedic.ch/swissmedic/en/home/news/mitteilungen/aktualisierte-anforderungen-umgang-nitrosamin-verunreinigungen.html